Two former FDA commissioners have publicly endorsed Heidi Overton as the right choice to lead the agency, according to an opinion piece published by STAT. The authors frame her nomination as arriving at a challenging time, but argue she has a genuine chance to bolster the FDA's effectiveness.
The commissioners do not dwell on specific policy proposals. Instead, they focus on Overton's fit for the role and the broader context, suggesting that her leadership could help steady the agency amid ongoing pressures. They stop short of detailing what changes she should pursue.
Their endorsement is notable because it comes from former officials who have seen the FDA's internal workings firsthand. While the piece is an opinion, it signals that at least some experienced regulators view Overton as a credible and constructive choice for the top job.